Consistent with the transcriptomic data, genetic alteration of SLC19A1 also suggests an unfavorable prognosis and is associated with several neoplastic biomarkers, including TMB, MSI, neoantigen, HRD, ploidy, and tumor purity. The gene discussed is SLC19A1; the disease is neoplasm.